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Introduction
The influenza infection is characterized by a high mu-
tation rate of the virus responsible for it which has the 
capability to evade the host immune response, causing 
the repetition of seasonal epidemics. Because of its high 
social impact, influenza seasonal epidemic represents a 
huge healthcare issue worldwide, being one of the ma-
jor causes of seasonal morbidity, hospitalizations and 
mortality, particularly in the elderly population. Aging 
subjects face a higher risk of complications because of 
the natural decline of their immune response and for this 
reason this population represents one of the main target 
for the annual influenza vaccination program in Italy.
The MF59 adjuvanted vaccine (Fluad®) is authorized in 
European countries since 1997, for the seasonal influ-
enza vaccination. MF59 adjuvant is an oil/water emul-
sion containing squalene, a metabolic intermediate of 
cholesterol synthesis, which is contained in the plasma 
membrane. Results of several clinical trials demonstrate 
a significant immunological superiority of this vaccine 
with respect to the traditional vaccine in the elderly pop-
ulation, because it induces a greater antibody response, 
particularly in the high-risk patients (people affected by 
chronic o degenerative diseases, such vascular, metabolic 
o respiratory diseases) [1, 2]. The MF59 adjuvanted vac-
cine confers also a higher protection versus heterovariant 
influenza virus strains, which correspond only partially 
to the strains included in the seasonal vaccine [3].
In recent years budget impact analyses has become an 
essential part of the economic evaluation of health care 
interventions. The purpose of such a pharmacoeconomic 
analysis is to evaluate the financial impact on health care 
expenditure (and thus the affordability for the payer) of 
the adoption of a new intervention with respect to other 
viable alternatives. The use of analytic models to per-
form the simulation of outcomes and associated costs, 
to better inform a comprehensive choice, is well estab-
lished  [4].
The aim of this study is the assessment of the financial 
budget impact of a seasonal vaccination program based 
on the use of the MF59 adjuvanted vaccine as compared 
with the traditional vaccine or the absence of vaccina-
tion in Italian elderly population.
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Summary
Introduction. Influenza vaccination has proven effective in the 
reduction of influenza-like illness (ILI) cases and influenza-re-
lated hospitalizations, drug consumption, primary care consulta-
tions and deaths in the elderly population. The aim of this study is 
the assessment of the financial budget impact of a seasonal vac-
cination program based on the use of the MF59 adjuvanted vac-
cine as compared with the traditional vaccine or the absence of 
vaccination in Italian elderly population.
Methods. A pharmacoeconomic simulation model was developed 
to simulate the effect of the three different vaccination programs 
during a single influenza season. Health economics and demo-
graphic data were taken from specific Italian sources, and vac-
cine effectiveness data derived from published literature. Direct 
medical costs were considered according to current Italian prices 
and tariffs.
Results. About 83% of the 12 million people of at least 65 years 
of age currently resident in Italy can be considered at high risk 
for influenza complications due to underlying chronic diseases. 
Absence of vaccination could lead to more than 2 million ILI 
cases, and 29,000 related deaths. The vaccination program with 
a coverage rate of 65.6% would lead to an estimated 1.5 million 
ILI cases (26.9% reduction) with a standard vaccine and to 1.3 
million (35.8% reduction) with the MF59 adjuvanted vaccine with 
a relative increase of avoided cases of 33,1%. The standard vac-
cination program produced a moderate direct cost increase of 
about 50 million Euro (+4.6%), whereas the adjuvanted vaccine 
provided an estimated saving of about 74 million Euro (-6.8%), 
both compared to the non vaccination. Cost savings were mainly 
related to hospital admissions avoided in the elderly population 
(≥ 65 years of age).
Conclusions. The vaccination with the MF59 adjuvanted vaccine 
resulted more effective and cost saving when compared with the 
standard vaccination and with no vaccination, thus representing 
the optimal strategy for the elderly population. The standard vac-
cine, even though a light cost increase, still proved to be effec-
tive compared to the null option, with the initial cost for the vac-
cination program nearly offset by healthcare resources savings 
obtained during the season.
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Methods
A pharmacoeconomic simulation model has been devel-
oped in Microsoft Excel to simulate the effect of three 
different vaccination programs in the Italian elderly 
population, during a single influenza season. Three al-
ternative programs have been evaluated: 1) the vaccina-
tion with a standard vaccine (split or sub-unit); 2) the 
vaccination with the MF59 vaccine; 3) no intervention. 
The principal effects of the vaccination considered in 
the model were related to the incidence of influenza-like 
illness (ILI) cases, influenza-related complications, and 
mortality. In detail the following events were simulated 
on the time horizon of influenza season: ILI cases; hospi-
talizations for influenza or pneumonia; hospitalizations 
for other respiratory diseases; hospitalizations for con-
gestive heart failure (CHF), acute coronary syndrome 
(ACS) or cerebrovascular accident (CVA); death for all 
causes, during the influenza season.
The administration of the vaccine during the autumnal 
season to a proportion of the elderly subjects (corre-
sponding to the coverage rate) has been simulated. Ef-
fectiveness data for both vaccines were derived from 
published literature, and referred to a first immunization. 
This implies that the potential protective effect related to 
the repetition of the vaccination in subsequent seasons 
was conservatively neglected.
An alternative scenario was also developed to account 
for the consequences of a flu epidemic caused by a het-
erovariant virus strain.
Population of the simulation
The simulation was run over the elderly resident Italian 
population (data as of 1st January 2010), corresponding 
to 12,206,470 subjects aged 65+ years [5]. The fraction 
of this population that could be considered at high risk 
for influenza-related complication due to the presence 
of other chronic condition was set to 82.6%, based on 
the data from a population study on health conditions, 
risk factors and use of the health services in Italy [6]. A 
65.6% coverage rate for the influenza vaccination in the 
Italian elderly population was considered, based on the 
data published by the Italian Ministry of Health for the 
season 2009-2010 [7].
Influenza in the non vaccinated 
population
The incidence of ILI cases among the non vaccinated 
population in Italy is largely unknown. Nonetheless some 
local data are available from the literature (Tab. I) [8, 10]. 
On the basis of these data a metanalysis was developed 
with a statistic Bayesian Random Effect model and the 
use of the WinBUGS software tool. In general, with this 
statistic model it is assumed that the outcomes recorded 
for the same phenomenon in different settings could be 
all ascribed to a common component (characteristic of 
the phenomenon in itself) added to random variations 
(specific of the settings). From the metanalysis the inci-
dence of ILI in one season in non vaccinated population 
resulted 16.8% (CI95%: 6.58-33.1%). Other pharmac-
oeconomic studies obtained similar estimates: a study 
from Scuffham and colleagues [11] used an incidence 
rate of 10% for the UK, France and Germany, a study 
from Piercy [12] used 5% for France, and another study 
from Baio used 16.58% for Italy [13].
Incidence rates for influenza related complications 
(Tab. II) derived from the data published by an early 
economic model of the economic impact of influenza 
vaccination in 25 European countries [14]. Regarding 
the ACS and CVA hospitalizations no data was found 
for Italy and thus we obtained the values from a Spanish 
case-control study, conducted in the Valencia province 
during the influenza season 2004-2005 [15], adapted in 
the hypothesis of a constant rate of events throughout 
the entire season.
Effectiveness of influenza vaccines
The effectiveness data for the standard vaccine derived 
from a comprehensive Cochrane review and metanaly-
sis [16], which examined published effectiveness stud-
ies in the prevention of influenza, ILI cases, hospitali-
zations, complications and mortality in people over 65 
years. 4,400 randomized, quasi-randomized, cohort and 
case-control studies published until the beginning of 
2006 were retrieved. 71 studies matched the inclusion 
criteria and were included in the published metanalysis. 
In the current budget impact analysis the effectiveness 
data for mortality and hospitalizations reductions were 
extracted from the metanalysis of cohort studies and 
expressed in terms of relative risk (RR) (Tab. II). For 
the reduction of ILI cases the effectiveness data derived 
from the metanalysis of Randomized Controlled Trials 
(RCT) were preferred. This choice was determined by 
the low quality and lack of homogeneity of the cohort 
studies analyzed, as evidenced in the published meta-
nalysis. Another consideration that, for ILI reduction, 
drove the choice for the metanalysis of RCTs instead of 
cohort studies was the intrinsic bias in them caused by 
the same definition of ILI which is solely based on clini-
cal, unspecific and not univocal symptoms.
For the MF59 adjuvanted vaccine no field study inves-
tigating the vaccine effectiveness in terms of reduction 
of ILI cases has been found. This lack of evidence is 
probably linked to the current regulatory asset in which 
the proof of immunogenicity for an influenza vaccine 
is considered a sufficient condition for market approv-
al in the US and Europe. In absence of other informa-
tion, effectiveness data for the adjuvanted vaccine was 
derived from the immunogenicity evidence, based on 
the relationship existing between protection rate and 
immunological power. The MF59 adjuvanted vaccine 
demonstrated in elderly people a superior immunogenic-
ity with respect to the standard vaccine in all the three 
viral strains currently circulating (AH3N2, AH1N1 and 
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B) [1, 2]. These immunogenicity data were converted in 
effectiveness rates, expressed as RR of ILI cases avoid-
ed [12, 17]. In the current budget impact analysis, the 
mean effectiveness value for the base case (relative to 
the B strain) was considered, whereas the others were 
considered for the sensitivity analysis.
The effectiveness data of the MF59 vaccine in reduc-
ing hospitalizations for influenza and pneumonia were 
obtained from a recent Italian population-based cohort 
study designed to compare the risk of hospitalization 
for influenza or pneumonia during the influenza sea-
son among elderly persons vaccinated with MF59 ad-
juvanted versus conventional sub-unit influenza vac-
cine. The study was conducted in three consecutive 
influenza seasons (2006-2009) through General Prac-
titioners or Local Health Authorities District offices 
and overall 170,816 person-seasons were recruited and 
analyzed. Results of the study showed an adjusted risk 
ratio for influenza and pneumonia hospitalization of 
0.77 (95%CI 0.59-0.99) for the MF59 vaccine relative 
to the traditional one [18]. In the current analysis the 
RR of the MF59 vs. no vaccination was calculated by 
multiplication of the RR of the standard vaccine vs. no 
vaccination by 0.77 (Tab. II).
The reduction of hospitalizations for ACS and CVA 
(Tab. II) derived from the already mentioned Spanish 
cohort study [15]. Finally, the effectiveness of the adju-
vanted vaccine in reducing mortality derived from the 
Pellegrini et al. metanalysis [19].
As long as it concerned hospitalizations for respiratory 
complications and for CHF, no data were found for the 
adjuvanted vaccine. We thus assumed that the two vac-
cines could have had the same outcomes per case of ILI. 
In this way the RR values for the adjuvanted vaccine 
were calculated by assuming the same number of CHF 
and respiratory complication events per ILI case as for 
the standard vaccine, respectively in high and low risk 
groups. As no data were found for the reduction of ACS 
and CVA hospitalizations for the standard vaccine, the 
same concept (with inverted roles) has been adopted to 
calculate their RR values.
Costs
In the budget impact analysis the perspective of the 
Italian National Healthcare System (SSN – Servizio 
Sanitario Nazionale) was adopted, therefore only direct 
medical costs were considered. In particular the analysis 
was performed accounting for the cost of acquisition and 
administration of the vaccines, the cost of the visits and 
of the pharmaceutical treatments for influenza and the 
cost for related hospitalizations (Tab. III).
Vaccine cost was valorized by the mean value of the bid 
prices in public tenders in years 2006-2009. The mean 
acquisition cost resulted in € 3.81 for a split or subu-
nit vaccine, and in € 5.58 for the adjuvanted vaccine. 
According to a national survey the influenza vaccine 
is administered in the GP’s room in 69.5% of the cases 
and in specific vaccine centers or other structures in the 
remaining part [20]. In the first case the administration 
cost was considered equivalent to the cost of one GP 
outpatient visit [21] plus the incentive granted by the 
Italian SSN to the GP to improve the diffusion of the 
influenza vaccination among the elderly people [22]. In 
case of vaccine administration in specific vaccine cent-
ers the cost was estimated by considering the monetary 
value of 5 minutes of work for a hospital attendant and 
for a medical specialist [23]. On the average the cost for 
vaccine administration resulted in € 16.23.
Tab. I. Italian population studies considered for the metanalysis of the infection rate.
ILI cases (n) Exposed subjects (n) Infection rate (%) Influenza season Geographic area Source
179 2,039 8.8% 2001-2002 Benevento city [8]
69 222 31.1% 1999-2000 Siena city [9]
37 206 18.0% 2000-2001 Siena city [9]
29 208 13.9% 2000-2001 liguria region [10]
11 79 13.9% 2000-2001 milano [10]
IlI: influenza-like illness.
Tab. II. outcome rates in the non vaccinated population and risk reductions (expressed as relative risk, rr) with the standard and adjuvanted 
mf59 vaccine in the elderly population at high/low risk for influenza-related complications.
Events No vaccine Standard vaccine MF59 vaccine
Rates for 100 
subjects
RR (Low Risk) RR (High Risk) RR (Low Risk) RR (High Risk)
IlI 16.8 0.59 0.59 0.47 0.45
I&p hospitalization 0.32 0.50 0.74 0.39 0.57
resp. hospitalization 1.08 0.84 0.85 0.68 0.65
chf hospitalization 0.23 0.79 0.92 0.64 0.70
acS hospitalization 0.33 0.89 0.94 0.72 0.72
cva hospitalization 0.51 0.87 0.91 0.70 0.70
mortality 0.24 0.65 0.39 0.46 0.27
IlI: influenza-like illness; acS: acute coronary syndrome; chf: congestive heart failure; cva: cerebrovascular accident; I&p: influenza and pneumonia; 
reSp: respiratory complications.
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A large population study [24] showed that in Italy about 
60% of the patients ask for a GP consultation in case of 
influenza [24] and that in about 66% of the cases these 
are domiciliary visits. Weighing the average costs of GP 
outpatient and domiciliary visits [21] with these findings 
resulted in an average visit cost per ILI case of € 12.83. 
Pharmaceutical treatment of influenza in general con-
sists of antiviral drugs, drugs used for the symptomatic 
therapy of the illness and antibiotics. Among these only 
antibiotic costs were considered in the budget impact 
analysis as the routine use of antiviral drugs is not rec-
ommended and symptomatic drugs (acetaminophen, 
non-steroidal anti-inflammatory drugs, cough drugs) are 
not currently reimbursed by the Italian SSN. The evalu-
ation of the costs for one antibiotic course was based 
on the resource consumptions recorded in two Italian 
cost-benefit studies [9, 10] valorized at current market 
prices [26].
Hospitalization costs for the Italian SSN were calculated 
considering national Diagnosis Related Group (DRG)
tariffs [27]. As each hospitalization corresponded to 
more than one DRG code, the tariffs were weighted with 
the relative occurrence frequencies in the Italian general 
population over 65 years as recorded in the Italian dis-
charge record database [28] (data 2005).
Mismatch scenario and sensitivity analysis
Influenza vaccines provide protection not only for in-
fluenza strains included in their formulations, but also 
for heterovariant virus strains, with a partially differ-
ent set of antigens. This effect varies depending on 
the antigenic difference between the two strains. The 
MF59 adjuvanted vaccine demonstrated in the eld-
erly population to provide a higher protection against 
heterovariant virus strains with respect to standard 
vaccine [29-31]. In the budget impact analysis an al-
ternative scenario was developed to evaluate the eco-
nomic performance of the vaccines in the hypothesis 
of a seasonal mismatch between the strains included 
in vaccines and the ones circulating. In this mismatch 
scenario the protection rate of the adjuvanted vaccine 
and standard was assumed to be limited at 85.5% and 
56% respectively. These percentages were derived 
from the mean of the seroprotection rates measured 
in two different studies which analyzed four different 
heterovariant strains [29, 30].
A one-way sensitivity analysis was worked out to assess 
the robustness of the results provided by the budget im-
pact model. In this analysis the model parameters were 
tested at the extremes of their CI95% when available. 
In the other case the parameters were tested in a ± 20% 
range, with some exceptions. The coverage rate was 
varied among the highest and lowest values recorded in 
Italian regions according the Italian Ministry of Health 
(Umbria: 77.5%; Friuli Venezia Giulia: 49.7%) [7]. The 
effectiveness of the adjuvanted vaccine in reducing ILI 
cases was varied by considering the protection rates 
demonstrated versus H3N2 and H1N1 viral strains, re-
spectively greater and lower than the mean effectiveness 
in the base case analysis (B strain). The proportion of 
vaccines administered by the GP or in vaccine centers 
was tested with the extremes recorded in Italian regions, 
according to the national survey (administration by GP; 
Lazio 93.4%; 5.3% Sardegna) [20]. The incentive for the 
GP was tested between 0 and € 10. Finally the hospitali-
zation costs were varied considering the highest and the 
lowest DRG tariffs in each category.
Results
The simulation with the budget impact model provided 
an estimate of the number of ILI cases, hospitalizations 
and deaths during an influenza season on the elderly 
Italian population (12 million subjects) (Tab. IV). The 
vaccination program with a coverage rate of 65.6% with 
the use of a traditional vaccine yielded a 26.9% reduc-
tion (about 552,000 cases) of ILI cases, while the MF59 
adjuvanted vaccine yielded a 35.8% reduction (about 
734,000 cases) with a relative increase of avoided cases 
of 33,1% (Fig. 1). On the mortality side the standard vac-
cine allowed reducing deaths by a 37.0% (10,700 deaths 
avoided) while the MF59 vaccine by a 45,6% (13,200 
deaths avoided), with a relative increase of 23.1%. The 
number of hospitalizations for influenza and/or pneumo-
nia was reduced by a 30.3% with the adjuvanted vac-
Tab. III. mean unitary costs considered in the study.
Outcome Mean cost (Euro)
Standard vaccine acquisition 3.81
adjuvanted vaccine acquisition 5.58
vaccine administration 16.23
visit cost per IlI case 12.83
pharmaceutical therapy per IlI case 3.21
hospitalization for I&p (drg 68, 69, 79, 80, 89, 90, 421) 3,916.63
hospitalization for resp. (drg 68, 69, 79, 80, 87, 89, 90, 92, 93, 94, 95, 96, 97, 101, 102) 3,448.10
hospitalization for chf (drg 127) 3,091.51
hospitalization for acS (drg 121, 122, 123, 140, 144, 145) 3,489.00
hospitalization for cva (drg 14, 15) 3,453.86
IlI: influenza-like illness; acS: acute coronary syndrome; chf: congestive heart failure; cva: cerebrovascular accident; I&p: influenza and pneumonia; 
reSp: respiratory complications; drg: diagnosis related group
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cine (19.8% with the standard vaccine), while the ACS 
and CVA hospitalizations respectively by the 18.6% and 
19.9% with the MF59 vaccine (4.6% and 6.2% with the 
standard vaccine). Finally the hospitalizations for respi-
ratory complications and CHF were reduced respective-
ly by a 22.7% and 20.3% with the adjuvanted vaccine 
(10.0% and 6.7% with the standard one).
Total costs resulted lightly higher with the standard vac-
cine than without vaccination, with an overall +4.6% 
increase (about + € 50.2 million), while the use of the 
MF59 vaccine yielded a net saving of -6.8% (about 
€ 74.0 million) with respect to non-vaccination (Tab. V). 
This means that, according to the results of this simula-
tion, the initial cost for the vaccination program with 
Tab. IV. IlI cases and related events in the base case and in the mismatch scenario, in the simulated population without vaccination, with the 
standard vaccination and with the mf59 vaccine.
Events No vaccine 
(n)
Standard vaccine
(n)
MF59 vaccine
(n)
Base case Scenario Base case Scenario
IlI 2,050,687 1,499,134 1,741,817 1,316,690 1,423,120 
I&p hospitalization 38,963 31,250 34,644 27,145 28,859 
resp. hospitalization 132,269 119,103 124,896 102,179 112,050 
chf hospitalization 28,299 26,394 27,233 22,551 24,787 
acS hospitalization 39,982 38,151 39,982 32,535 33,615 
cva hospitalization 62,776 58,862 62,776 50,285 52,096 
IlI: influenza-like illness; acS: acute coronary syndrome; chf: congestive heart failure; cva: cerebrovascular accident; I&p: influenza and pneumonia; 
reSp: respiratory complications.
Tab. V. total costs (euro) in the base case and in the mismatch scenario for the simulated population due to IlI cases and related events, with 
use of the standard vaccine, the adjuvanted vaccine and for no vaccination.
Items No vaccine
(Euro)
Standard vaccine
(Euro)
MF59 vaccine
(Euro)
Base case Scenario Base case Scenario
vaccine - 160,501,294 160,501,294 174,674,471 174,674,471 
gp visits 26,306,212 19,230,893 22,344,034 16,890,500 18,255,778 
antibiotics 6,582,705 4,812,221 5,591,234 4,226,575 4,568,214 
I&p hospitalization 152,603,859 122,395,229 135,687,027 106,318,344 113,029,744 
resp. hospitalization 456,077,804 410,679,163 430,654,565 352,324,209 386,358,084 
chf hospitalization 87,488,126 81,598,537 84,189,956 69,715,870 76,628,401 
acS hospitalization 139,498,653 133,108,579 139,498,653 113,516,338 117,283,774 
cva hospitalization 216,819,969 203,302,166 216,819,969 173,675,686 179,931,607 
tot 1,085,377,329 1,135,628,083 1,195,286,732 1,011,341,993 1,070,730,072 
IlI: influenza-like illness; acS: acute coronary syndrome; chf: congestive heart failure; cva: cerebrovascular accident; I&p: influenza and pneumonia; 
reSp: respiratory complications; gp: general practioners
Fig. 1. relative reductions of influenza related events obtained 
through the model simulation over the Italian elderly population 
along one influenza season with the standard and mf59 adjuvan-
ted vaccines vs. the choice of no vaccine.
IlI: influenza-like illness; acS: acute coronary syndrome; chf: conges-
tive heart failure; cva: cerebrovascular accident; I&p: influenza and 
pneumonia; reSp: respiratory complications.
Fig. 2. differences in total costs, acquisition and administration 
costs, visits and pharmaceutical treatment costs and hospitaliza-
tion costs obtained through the model simulation over the Italian 
elderly population along one influenza season with the standard 
and mf59 adjuvanted vaccines vs. the choice of no vaccine.
IlI: influenza-like illness.
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the standard vaccine was nearly offset by healthcare re-
sources savings obtained during the season. In the case 
of the MF59 vaccine the initial cost was totally offset, 
yielding to a final net saving (Fig. 2).
In the mismatch scenario, an influenza season with only 
heterovariant circulating virus strains was analyzed. In 
this alternative scenario, ILI cases and hospitalization 
events resulted more numerous than in base case for both 
the standard and adjuvanted vaccine due to their reduced 
protection against the heterovariant strain (Tab. V). Also 
on the cost side of the analysis the mismatch scenario got 
worse results as the total budget for one influenza season 
increased by +10.1% (about + € 109.9 million) with the 
standard vaccine vs. no vaccine. With the MF59 vac-
cine the final result is still a net saving of -1.3% (about 
€ 14.6 million).
The one-way sensitivity analysis was performed on the 
total budget impact of the MF59 adjuvanted vaccination 
vs. no vaccination (base-case value was € -74 million). 
The results of this analysis, presented as tornado graph-
ic, show an overall good stability of model’s findings 
(Fig. 3). The parameter which can affect more the result 
is the unitary cost for hospitalization related to respira-
tory complications. In any case, under none of the varia-
tions considered, for model parameters the budget impact 
analysis of MF59 vs. no vaccination reversed its sign, 
meaning a relevant robustness of the final conclusion: the 
strategy has the capability of saving money. Interestingly 
enough in this analysis the purchasing cost of the MF59 
vaccine is not among the most influential parameters in 
the model, as it is quite usual to see in budget impact mod-
els, supporting again the robustness of the conclusion.
Fig. 3. one-way sensitivity analysis on the total budget impact of the mf59 adjuvanted vaccination vs. no vaccination (base case value: € -74 
million).
IlI: influenza-like illness; acS: acute coronary syndrome;  chf: congestive heart failure; cva: cerebrovascular accident; I&p: influenza and pneumonia; 
reSp: respiratory complications; hosp: hospitalization; adm: administration; rr: relative risk; hr: high risk group; lr: low risk group; cov.: coverage; 
vc: vaccine center; pharm. ther.: pharmaceutical therapy; gp: general practioners.
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Discussion and conclusion
A large number of clinical and field studies highlights 
the importance of influenza vaccination programs among 
the elderly population. The results of the present budget 
impact analysis support this concept: the acquisition and 
administration costs to conduct a program with a standard 
vaccine are almost offset by the savings in other healthcare 
resources in one season. In the case of the MF59 adjuvant-
ed vaccine those costs are more than repaid by the savings 
due to avoided hospitalizations. The same economic con-
clusion is reached under the mismatch scenario and the 
variations tested in the sensitivity analysis, demonstrating 
the good economic value of this type of vaccine.
In this budget impact analysis the cost perspective of 
the Italian SSN is adopted, so that only direct medical 
costs are considered. Nonetheless the vaccination pro-
gram can induce a saving in costs that are directly borne 
by the patient or the family, like private visits or symp-
tomatic treatments, not reimbursed by the Italian SSN. 
Indirect cost, such as reduced productivity, absenteeism 
or familiar care giving, can also play an important role in 
the definition of the total burden of influenza. The rou-
tine vaccination could also reduce the seasonal impact 
of these costs, which were not considered in the present 
analysis. It is very likely that if all the direct medical, pa-
tient-borne and indirect costs were considered and thus a 
broader social perspective adopted, also the vaccination 
program with the standard vaccine would result in a total 
net saving with respect the non-vaccination.
The major limitation of this analysis is related to the in-
trinsic and largely unavoidable limits of the modeling 
approach which invariably involves the use of multiple 
and non-homogeneous sources, extrapolation of data 
and, when no other information is available, the necessi-
ty for assumptions. These limits are common to all eco-
nomic studies based on models. In general it is clear that 
the results of a model cannot be regarded by any mean 
as an absolute effectiveness claim, since the ultimate ob-
jective of a model-based economic analysis is always the 
comparative assessment of costs and outcomes of two or 
more healthcare technologies evaluated under the same 
set of assumptions (i.e. the model).
In conclusion, the use of MF59 adjuvanted vaccine in 
the place of the traditional vaccine for the routine sea-
sonal influenza vaccination of the elderly population 
represents an effective option under both the clinical and 
the economic points of view.
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